ArticleOrphanet journal of rare diseases2025
Unraveling the molecular landscape of congenital pseudoarthrosis of the tibia: insights from a comprehensive analysis of 159 probands.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Extent of the low-density line is associated with time to fracture in children with congenital anterolateral bowing of the tibia: a retrospective survival analysis.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCongenital pseudarthrosis of the tibia (CPT, HP:0009736), commonly known as bowing of the tibia, is a rare congenital tibia malformation characterized by spontaneous tibial fractures and difficulty in reunion after tibial fractures during early childhood, with a prevalence between 1/250,000 and 1/140,000. While 80%-84% of CPT cases present with neurofibromatosis type 1, caused by the variations in the NF1 gene, the underlying cause of CPT remains unclear. Considering its congenital nature and the low prevalence, we hypothesized that the rare genomic protein-damaging variations may contribute to CPT.
resultsIn this study, we conducted whole exome sequencing on 159 patients with CPT and found loss-of-function (LoF) excesses in the 159 patient cases compared to 208 healthy controls from the 1000 Genomes Project. The LoF variant types primarily included stop-gained and frameshift variants, both present in 97% of the 159 patients with CPT, as well as splice-changing variants, which were found in 78% of these patients. Rare LoF variations in osteocyte-related pathways, such as ossification, were identified in 112 of the 159 CPT cases (70.4%). The top seven genes carrying rare protein-damaging variants that might be related to CPT are NF1, GLI3, MRC2, PTH1R, RYR1, NPR2 and ITGA11.
conclusionsThese findings shed light on novel genetic mutations and osteocyte transcriptome-related molecular pathways involved in CPT, providing a new framework for understanding the genetic regulation of CPT pathology and suggesting potential directions to further elucidate its pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.